Vandetanib 300mg
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Conditions
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Trial Timeline
Nov 1, 2012 → Jul 1, 2014
NCT ID
NCT01661179About Vandetanib 300mg
Vandetanib 300mg is a phase 1/2 stage product being developed by Sanofi for Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01661179. Target conditions include Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma.
What happened to similar drugs?
1 of 20 similar drugs in Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01661179 | Phase 1/2 | Completed |
Competing Products
20 competing products in Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma